Form 10-QSB
[As last amended in Release No. 33-7505,
effective January 1, 1999, 63 F.R. 9632.]
U.S. Securities and Exchange Commission
Washington, D.C. 20549
Form 10-QSB
(Mark One)
[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended November 30, 2002
[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT
For the transition period from N/A to N/A
----- -----
Commission file number 000 - 28385
Protalex, Inc.
--------------
(Exact name of small business issuer as
specified in its charter)
New Mexico 91-2003490
---------- ----------
(State or other jurisdiction (IRS Employer
of incorporation or organization) Identification No.)
P.O. Box 30952, Albuquerque, NM 87190
(Address of principal executive offices)
(505) 243-8220
(Issuer's telephone number)
(Former name, former address and former fiscal year,
if changed since last report)
Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Yes X No
-------- --------
APPLICABLE ONLY TO CORPORATE ISSUERS
State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date: Common Stock, no Par Value,
12,272,711 as of November 30, 2002.
Transitional Small Business Disclosure Format (check one):
Yes No X
-------- --------
PART 1
ITEM 1 - FINANCIAL STATEMENTS
Protalex, Inc.
(A Company in the Development Stage)
BALANCE SHEET
(Unaudited)
November 30, 2002
ASSETS
CURRENT ASSETS
Cash and cash equivalents ..................... $ 868,499
Prepaid expense ............................... 38,617
Deposits ...................................... 2,815
----------
Total current assets ................... $ 909,931
EQUIPMENT
Lab equipment ................................. 187,555
Office and computer equipment ................. 131,829
Furniture and fixtures ........................ 21,268
Leasehold improvements ........................ 10,685
----------
351,337
Less accumulated depreciation ................. (237,833) 113,504
----------
OTHER ASSETS
Intellectual technology license, net of
accumulated amortization of $3,131 .......... 17,169
----------
$1,040,604
==========
LIABILITIES
CURRENT LIABILITIES
Accounts payable .............................. $ 102,234
Accrued compensation .......................... 61,186
Current maturities of long-term liabilities ... 20,318
Payroll and withholding taxes payable ......... 349
Interest payable .............................. 97
-----------
Total current liabilities .............. $ 184,184
STOCKHOLDERS' EQUITY
Common stock, no par value, authorized
40,000,000 shares, 12,570,735 shares
issued, 12,272,711 shares outstanding ....... 3,755,892
Common stock, contra .......................... (368,547)
Treasury stock, 298,024 shares ................ (41,667)
Additional paid-in-capital .................... 183,569
Deficit accumulated during the
development stage ........................... (2,672,827) 856,420
----------- -----------
$ 1,040,604
===========
Protalex, Inc.
(A Company in the Development Stage)
STATEMENTS OF OPERATIONS
For the Six Months and Three Months Ended November
30, 2002 and 2001 and Period from Inception
(September 17, 1999) through November 30, 2002
Six Six Three Three From Inception
Months Ended Months Ended Months Ended Months Ended Through
November 30, November 30, November 30, November 30, November 30,
2002 2001 2002 2001 2002
------------- ------------- ------------- ------------- -------------
Revenues $ - $ - $ - $ - $ -
Operating Expenses
Research and development (488,182) (366,850) (292,772) (107,423) (1,981,797)
Administrative (167,625) (37,893) (79,546) (16,281) (368,597)
Professional fees (41,617) (62,700) (8,621) (6,091) (247,285)
Depreciation and amortization (7,105) (9,015) (2,451) (8,795) (42,302)
-------------- ------------- ------------- ------------- -------------
Operating Loss (704,529) (476,458) (383,390) (138,590) (2,639,981)
Other income (expense)
Interest income 5,885 3,979 3,520 5,504 36,163
Interest expense (1,644) (6,167) (328) (6,581) (59,990)
Loss on disposal (9,019) - (6,727) - (9,019)
-------------- ------------- ------------- ------------- -------------
NET LOSS $ (709,307) $ (478,646) $ (386,925) $ (139,667) $ (2,672,827)
============= ============= ============= ============= =============
Weighted average number of
common shares outstanding $ 12,145,373 $ 10,720,046 $ 12,284,748 $ 10,608,635 $ 10,183,274
============= ============= ============= ============= =============
Loss per common share $ (.06) $ (.04) $ (.03) $ (.01) $ (.26)
============= ============= ============= ============= =============
Protalex, Inc.
(A Company in the Development Stage)
STATEMENTS OF CASH FLOWS
(Unaudited) For the
Six Months Ended November 30, 2002 and
2001
and from Inception (September 17, 1999) through November 30, 2002
Six Six From Inception
Months Ended Months Ended Through
November 30, November 30, November 30,
2002 2001 2002
----------- ----------- ----------
Cash flows from operating activities
Net loss ........................................ $ (709,307) $ (478,646) $(2,672,827)
Adjustments to reconcile net loss to net
cash (used in) operating activities
Depreciation and amortization ............... 57,156 55,077 253,781
Non cash expenses ........................... -- -- 16,644
Loss on disposal ............................ 9,021 -- 9,021
(Increase) decrease in prepaid expense ...... (39,830) 6,218 (41,432)
Increase (decrease) in payroll taxes payable (1,996) (4,131) 349
Increase in accounts payable ................ 46,128 9,080 102,233
(Decrease) increase in interest payable ..... (456) (1,398) 97
Increase in accrued compensation ............ 49,686 3,838 61,186
----------- ----------- -----------
Net cash (used in) operating activities . (589,598) (409,962) (2,270,948)
----------- ----------- -----------
Cash flows from investing activities
Acquisition of intellectual technology license
- fee portion ................................. -- -- (20,000)
Acquisition of equipment ........................ (12,424) (21,511) (288,069)
Excess of amounts paid for public shell
over assets acquired to be accounted for
as a recapitalization ......................... -- -- (250,000)
Proceeds on disposal of equipment ............... 6,326 -- 6,326
----------- ----------- -----------
Net cash (used in)
investing activities .................. (6,098) (21,511) (551,743)
----------- ----------- -----------
Cash flows from financing activities
Additional paid-in-capital ...................... -- 143,569 183,569
Proceeds from stock issuance .................... 1,263,001 1,102,000 3,620,401
Purchases of treasury stock ..................... (41,667) -- (41,667)
Principal payment on note payable to individual . -- (142,830) (225,717)
Issuance of note payable to individual .......... -- -- 368,546
Principal payment on installment purchase payable (19,006) -- (213,942)
Principal payment on equipment note payable ..... -- (7,195) --
----------- ----------- -----------
Net cash provided by financing
activities ............................ 1,202,328 1,095,544 3,691,190
----------- ----------- -----------
NET INCREASE IN CASH .............................. 606,632 664,071 868,499
Cash and cash equivalents, beginning of period .... 261,867 212,254 --
----------- ----------- -----------
Cash and cash equivalents, end of period .......... $ 868,499 $ 876,325 $ 868,499
=========== =========== ===========
Protalex, Inc.
(A Company in the Development Stage)
STATEMENTS OF CASH FLOWS - CONTINUED
(Unaudited)
For the Six Months Ended November 30,
2002 and 2001 and from Inception (September 17,
1999) through November 30, 2002
Six Six From Inception
Months Ended Months Ended Through
November 30, November 30, November 30,
2002 2001 2002
----------------- ---------------- -----------------
Interest paid $ 1,643 $ 7,565 $ 56,792
================= ================ =================
Taxes paid $ - $ - $ 50
================= ================ =================
SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING ACTIVITIES
10,000 shares of company stock were
issued as part of the cost of acquisition
of the intellectual technology license at
inception - value at $.03 per share $ - $ - $ 300
================= ================ =================
100,000 shares of company stock were
issued in exchange for legal services
performed $ - $ - $ 15,000
================= ================ =================
1,644 shares of company stock were
issued in exchange for interest payable $ - $ - $ 1,644
================= ================ =================
Lab equipment was acquired through
issuance of installment contract to seller $ - $ - $ 91,430
================= ================ =================
Protalex, Inc.
(A Company in the Development Stage)
NOTES TO FINANCIAL STATEMENTS
(Unaudited)
From Inception (September 17, 1999) through November 30, 2002
NOTE A - NOTES TO INTERIM FINANCIAL STATEMENTS
The interim financial data is unaudited, however in the opinion of
management, the interim data includes all adjustments, consisting of normal
recurring adjustments, necessary for a fair statement of the results for the
interim period. The financial statements included herein have been prepared
by the Company pursuant to the rules and regulations of the Securities and
Exchange Commission. Certain information and footnote disclosures normally
included in financial statements prepared in accordance with accounting
principles generally accepted in the United States of America have been
omitted pursuant to such rules and regulations, although the Company
believes that the disclosures included herein are adequate to make the
information presented not misleading.
The organization and business of the Company, accounting policies followed
by the Company and other information are contained in the notes to the
Company's financial statements filed as part of the Company's May 31, 2002
Form 10-KSB. This quarterly report should be read in conjunction with such
annual report.
NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
1. Estimates
The preparation of financial statements in conformity with accounting
principles generally accepted in the United States of America requires the
Company to make estimates and assumptions affecting the reported amounts of
assets, liabilities, revenues and expense, and the disclosure of contingent
assets and liabilities. Estimated amounts could differ from actual results.
2. Loss per Common Share
The Financial Accounting Standards Board (FASB) has issued Statement of
Financial Accounting Standards No. 128 "Earnings Per Share" (SFAS No. 128)
which is effective for periods ending after December 15, 1997. SFAS No. 128
provides for the calculation of " Basic" and "Diluted" earnings per share.
Basic earnings per share includes no dilution and is computed by dividing
loss to common shareholders by the weighted average number of common shares
outstanding for the period. All potentially dilutive securities have been
excluded from the computations since they would be antidilutive. However,
these dilutive securities could potentially dilute earnings per share in the
future.
Protalex, Inc.
(A Company in the Development Stage)
NOTES TO FINANCIAL STATEMENTS - CONTINUED
(Unaudited)
From Inception (September 17, 1999) through November 30, 2002
NOTE C - GOING CONCERN UNCERTAINTY
The accompanying financial statements have been prepared in conformity with
accounting principles generally accepted in the United States of America,
which contemplate continuation of the Company as a going concern. The
Company is a development stage enterprise and does not have operating
revenue nor anticipate generating operating revenue for the foreseeable
future. There is substantial doubt about the ability of the Company to
continue as a going concern. This ability to continue as a going concern is
dependent initially on its ability to raise sufficient investment capital to
fund all necessary operations and product development activities. Secondly,
the Company must develop products that are regulatory approved and market
accepted to generate operating revenue. There is no assurance that these
plans will be realized in whole or in part. The financial statements do not
include any adjustments that might result from the outcome of these
uncertainties.
NOTE D - STOCK OPTIONS
All options issued are "stand alone" options. There is no Company stock
option plan currently. The Company accounted for the options to employees
using the "intrinsic" method which records as compensation cost the
difference between exercise price of the options and the fair market value
of Company stock on the measurement (grant) date. Options to non-employees
are accounted for using the "fair value" method, which recognizes the value
of the option as an expense over the expected life of the option with a
corresponding increase to paid-in capital.
On October 24, 2002 the Company issued stock options to a director. The
options vested immediately and have a term of ten years and an exercise
price of $1.45 per share. The Company accounted for the options in
accordance with APB Opinion No. 25 and has recognized compensation expense
based on the "intrinsic value" method. This method records compensation cost
as the difference between the exercise price of the option and the fair
market value of the Company's stock on the measurement (grant) date. No
compensation expense was recorded during the quarter ended November 2002 for
these options as there was no difference between the exercise price of the
option and the fair market value of the Company's stock on the grant date.
Protalex, Inc.
(A Company in the Development Stage)
NOTES TO FINANCIAL STATEMENTS - CONTINUED
(Unaudited)
From Inception (September 17, 1999) through November 30, 2002
NOTE D - STOCK OPTIONS - CONTINUED
Had the Company determined compensation expense based on the fair value at
the measurement date for its stock options under Statement of Financial
Accounting Standards No. 123, the Company's net loss and loss per share
would have increased to the proforma amounts indicated as follows:
Six Six From Inception
Months Ended Months Ended Through
November 30, November 30, November 30,
2002 2001 2002
---------- ---------- -----------
Net loss, as reported ........ $(709,307) $(478,646) $(2,672,827)
Proforma net loss ............... (757,201) (478,646) (2,728,117)
Loss per share, as reported ..... (.06) (.04) (.26)
Proforma loss per share ......... (.06) (.04) (.26)
The fair value of the options are estimated on the date of the grant using
the Black-Scholes option pricing model with the following assumptions:
dividends of $0 per year; expected volatility of 83-96 percent; risk-free
interest rate of 4.16-5.07 percent; and an expected life of three-five
years.
A summary of the common stock option activity for an officer and two
non-employee directors is as follows:
Weighted
Average
Exercise
Options Prices Exercisable
---------- ----------- -----------
Balance, August 31, 2002 458,680 1.45 458,680
Granted during the period 100,000 1.45 100,000
---------- -----------
Balance, November 30, 2002 558,680 558,680
=========== ===========
NOTE E - SUBSEQUENT EVENT
1. On December 16, 2002, the Company issued "free standing" common stock
options to each Director ("Optionee") of 10,000 common shares @ $1.70
per share for a 10-year period.
Protalex, Inc.
(A Company in the Development Stage)
NOTES TO FINANCIAL STATEMENTS - CONTINUED
(Unaudited)
From Inception (September 17, 1999) through November 30, 2002
NOTE E - SUBSEQUENT EVENT - CONTINUED
2. An amendment to the Company's Bylaws was passed to allow for a
minimum of five (5) Directors and a maximum of seven (7) Directors.
3. Steven H. Kane, of New Hope, PA was appointed as the Company's new
President and CEO on December 16, 2002 at the annual meeting of the
Board of Directors.
Protalex, Inc.
(A Company in the Development Stage)
PART 1
ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS INCLUDING PLAN OF OPERATION
The Company's principal activities consist of preparing for a Company sponsored
investigational new drug (IND) application for treating Rheumatoid Arthritis
(RA) to be submitted to the FDA in the third quarter of 2003 and continued
laboratory research and development on its bioregulator technology. The Company
continues to pursue a balance of in-house and outsourced research addressing FDA
requirements for the Company's IND application, gathering data for other
possible diseases, and generally broadening its intellectual property base.
The Company estimates it has sufficient cash reserves for 6 months of normal
operation. The raising of an additional $5-$8,000,000 is planned during the
first half of 2003 to fund FDA Phase I/II clinical trials, along with continued
implementation of research plans and execution of a broader patent strategy.
A pre-clinical animal safety study for Rheumatoid Arthritis is underway, and an
animal study to refine product formulation is complete. After reviewing sourcing
options for the components of our drug formulation, Protalex has determined that
producing our own raw materials will strengthen our IND application package.
The Company is contracting with an FDA approved laboratory to produce the raw
material for its drug, a process that should be completed by mid-2003.
Meanwhile, in-house laboratory work to fulfill FDA requirements continues, both
in the area of drug formulation and stability, and for developing measures of
immunogenicity. The Company plans to hire a chemist in the first quarter of 2003
to assist with drug analysis and formulation.
Please refer to the Company's 10-KSB filing (May 31, 2002) for more information
on the Company's technology and risk factors.
PART 1
ITEM 3 - CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures:
Disclosure controls and procedures are designed and implemented to insure that
all material information relating to a company is made known to its president,
chief financial officer, and such other persons who are responsible for
preparing and filing periodic reports with the Securities and Exchange
Commission. On October 11, 2002, John E. Doherty and Donald K. Dean,
representing all of the officers and directors of Protalex, Inc., evaluated
Protalex's disclosure controls and procedures and concluded that such controls
were adequate as of that date.
Changes in Internal Control:
There have been no significant changes in Protalex's internal controls or in
other factors that could significantly affect these controls subsequent to the
date of their evaluation, including any corrective actions with regard to
significant deficiencies and material weaknesses.
Protalex, Inc.
(A Company in the Development Stage)
PART 2
ITEM 6- EXHIBITS AND REPORTS ON FORM 8-K
6.A Index of Exhibits - From 10-K
- -------------------------------------------------------------------------
2.1 Stock Purchase Agreement Incorporated by reference,
among Protalex, Inc., to the Company's 10-SB
Don Hanosh and Enerdyne filing December 3, 1999
Corporation
- -------------------------------------------------------------------------
Merger Agreement and Plan Incorporated by reference
of Re-organization to the Company's 10-SB
between Protalex, Inc. filing December 3, 1999
and Enerdyne Corporation
- -------------------------------------------------------------------------
3.1 Articles of Incorporation, Incorporated by reference
as amended to the Company's 10-SB
filing December 3, 1999
- -------------------------------------------------------------------------
10.1 Promissory Note in favor Incorporated by reference
of Don Hanosh to the Company's 10-SB
filing December 3, 1999
- -------------------------------------------------------------------------
10.2 Continuing and Unconditional Incorporated by reference,
Guaranty executed by John to the Company's 10-SB
E. Doherty filing December 3, 1999
- -------------------------------------------------------------------------
10.3 Continuing and Unconditional Incorporated by reference,
Guaranty executed by James to the Company's 10-SB
K. Strattman filing December 3, 1999
- -------------------------------------------------------------------------
10.5 Form of Confidential Disclosure Incorporated by reference,
Agreement to the Company's 10-SB
filing December 3, 1999
- -------------------------------------------------------------------------
Exhibit
Number Exhibit Name
6.B A report on Form 8-K was filed on August 24,
2002, which detailed the departure of Paul
Mann, previous Chief Scientific Officer.
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
PROTALEX, INC.
DATE: January 13, 2003 BY: John E. Doherty
---------------- ----------------------
John E. Doherty
President and Director
CERTIFICATION OF THE 10-QSB BY THE PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL
FINANCIAL OFFICER -NEW EXCHANGE ACT RULES 13A-
14, 15D-14
I, John E. Doherty, certify that:
1. I have reviewed this quarterly report on Form 10-QSB of
Protalex, Inc.;
2. Based on my knowledge, this quarterly report does not contain
any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light
of the circumstances under which such statements were made,
not misleading with respect to the period covered by this
quarterly report;
3. Based on my knowledge, the financial statements, and other
financial information included in this quarterly report,
fairly present in all material respects the financial
condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this
quarterly report;
4. The registrant's other certifying officers and I are
responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules
13a-14 and 15d-14) for the registrant and have:
a. designed such disclosure controls and procedures to ensure
that material information relating to the registrant, is made
known to us by others, particularly during the period in which
this quarterly report is being prepared;
b. evaluated the effectiveness of the registrant's disclosure
controls and procedures as of a date within 90 days prior to
the filing date of this quarterly report (the "Evaluation
Date"); and
c. presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based
on our evaluation as of the Evaluation Date;
5. The registrant's other certifying officers and I have
disclosed, based on our most recent evaluation, to the
registrant's auditors and the audit committee of registrant's
board of directors (or persons performing the equivalent
functions):
a. all significant deficiencies in the design or operation of
internal controls which could adversely affect the
registrant's ability to record, process, summarize and report
financial data and have identified for the registrant's
auditors any material weaknesses in internal controls; and
b. any fraud, whether or not material, that involves management
or other employees who have a significant role in the
registrant's internal controls; and
CERTIFICATION OF THE 10-QSB BY THE PRINCIPAL EXECUTIVE OFFICER
AND PRINCIPAL FINANCIAL OFFICER -NEW EXCHANGE ACT RULES 13A-
14, 15D-14 - CONTINUED
6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in
internal controls or in other factors that could significantly affect
internal controls subsequent to the date of our most recent evaluation,
including any corrective actions with regard to significant
deficiencies and material weaknesses.
Date: January 13, 2003
John E. Doherty
------------------------------
John E. Doherty
President and Director
CERTIFICATION OF THE 10-QSB BY THE PRINCIPAL EXECUTIVE OFFICER AND
PRINCIPAL FINANCIAL OFFICER - CONTINUED
I, Donald K. Dean, certify that:
1. I have reviewed this quarterly report on Form 10-QSB of
Protalex, Inc.;
2. Based on my knowledge, this quarterly report does not contain
any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light
of the circumstances under which such statements were made,
not misleading with respect to the period covered by this
quarterly report;
3. Based on my knowledge, the financial statements, and other
financial information included in this quarterly report,
fairly present in all material respects the financial
condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this
quarterly report;
4. The registrant's other certifying officers and I are
responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules
13a-14 and 15d-14) for the registrant and have:
a. designed such disclosure controls and procedures to ensure
that material information relating to the registrant, is made
known to us by others, particularly during the period in which
this quarterly report is being prepared;
b. evaluated the effectiveness of the registrant's disclosure
controls and procedures as of a date within 90 days prior to
the filing date of this quarterly report (the "Evaluation
Date"); and
c. presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based
on our evaluation as of the Evaluation Date;
5. The registrant's other certifying officers and I have
disclosed, based on our most recent evaluation, to the
registrant's auditors and the audit committee of registrant's
board of directors (or persons performing the equivalent
functions):
a. all significant deficiencies in the design or operation of
internal controls which could adversely affect the
registrant's ability to record, process, summarize and report
financial data and have identified for the registrant's
auditors any material weaknesses in internal controls; and
b. any fraud, whether or not material, that involves management
or other employees who have a significant role in the
registrant's internal controls; and
CERTIFICATION OF THE 10-QSB BY THE PRINCIPAL EXECUTIVE OFFICER
AND PRINCIPAL FINANCIAL OFFICER - CONTINUED
6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in
internal controls or in other factors that could significantly affect
internal controls subsequent to the date of our most recent evaluation,
including any corrective actions with regard to significant
deficiencies and material weaknesses.
Date: January 13, 2003
Donald K. Dean
------------------------------
Donald K. Dean
Treasurer and Chief Financial Officer
CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
I, John E. Doherty, President of Protalex, Inc. certify in my capacity as an
officer of Protalex that I have reviewed the quarterly report of Protalex on
Form 10-QSB for the six month period ended November 30, 2002 and that to the
best of my knowledge:
1. the report fully complies with the requirements of the Securities
Exchange Act of 1934; and
2. the information contained in the report fairly presents, in all
material respects, the financial condition and results of operations of
Protalex.
The purpose of this statement is solely to comply with Title 18, Chapter 63,
Section 1350 of the United States Code, as amended by Section 906 of the
Sarbanes-Oxley Act of 2002.
Date: January 13, 2003 BY: John E. Doherty
---------------- ----------------------
John E. Doherty
President and Director
CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
I, Donald K. Dean, Treasurer and Chief Financial Officer of Protalex, Inc.
certify in my capacity as an officer of Protalex that I have reviewed the
quarterly report of Protalex on Form 10-QSB for the six month period ended
November 30, 2002 and that to the best of my knowledge:
1. the report fully complies with the requirements of the Securities
Exchange Act of 1934; and
2. the information contained in the report fairly presents, in all material
respects, the financial condition and results of operations of Protalex.
The purpose of this statement is solely to comply with Title 18, Chapter 63,
Section 1350 of the United States Code, as amended by Section 906 of the
Sarbanes-Oxley Act of 2002.
Date: January 13, 2003 BY: Donald K. Dean
---------------- ---------------------------
Donald K. Dean
Treasurer and Chief Financial Officer